Join us as we introduce a diverse panel, bringing together different perspectives of the industry, to provide their insights on what the removal of cannabis from the German Narcotics List really means. What changes are to be expected by patients, pharmacists, physicians and the industry as a whole? Does the reclassification provide opportunities for the industry or is it just another reason for hype? We will take a closer look at this decision by the German government and discuss its implications.

Language: German

Speakers

• Bijan Christoph Hezarkhani (Moderator), BijanChristoph.com, Business Development
• Dr. Armin Prasch, (Speaker), Trias Pharma GmbH, CEO
• Thorsten Hetfeld (Speaker), CannaTHoC Cannabis-Association, Founder
• Melanie Dolfen, (Speaker), Bezirksapotheken Berlin, Pharmacist & Owner & Entrepreneur
• Garvin Hirt (Speaker), Copeia, Founding Partner